Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
-190.93%
-568.76%
121.35%
54.82%
35.41%
26.15%
ROA
-150%
-224.15%
-
-
-
-
Total Assets
SEK 30,156.00K
SEK 2,761.00K
SEK 2,761.00K
SEK 2,761.00K
SEK 2,761.00K
SEK 2,761.00K
Sector average
SEK 2,857,190.78K
SEK 2,900,240.60K
SEK 3,045,009.79K
SEK 3,280,286.42K
SEK 3,536,407.14K
SEK 3,762,908.71K
Net Income
-SEK 36,893.00K
-SEK 36,891.36K
-SEK 36,901.45K
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for Annexin Pharmaceuticals AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
-SEK 36,901.33K
-SEK 36,901.18K
-SEK 36,900.91K
Sector average
-SEK 2,851.32K
-SEK 22,027.28K
-SEK 904.69K
-SEK 7,253.84K
-SEK 3,858.45K
-SEK 1,547.00K
Valuation
SEK 172,620.00K
SEK 172,612.33K
SEK 172,659.52K
SEK 172,658.99K
SEK 172,658.26K
SEK 172,657.02K
Sector average
SEK 3,960,502.41K
SEK 5,151,301.60K
SEK 5,189,236.02K
SEK 5,317,343.69K
SEK 5,514,329.75K
SEK 5,636,782.17K
Stock Price
SEK 19.80
SEK 19.80
SEK 19.80
SEK 19.80
SEK 19.80
SEK 19.80
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
Annexin Pharmaceuticals AB (publ) (ANNX.ST) Financial Forecast | Equlion
